GI Cancers Symposium

A starting dose of regorafenib (Stivarga) 80 mg daily with dose escalation to 160 mg daily was better tolerated than starting at 160 mg daily, with a trend toward improved survival in the management of patients with metastatic colorectal cancer. Read More ›

The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provides durable clinical benefit in patients with previously treated DNA mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC). Read More ›





Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: